Keywords: rituxan, slows, joint, damage, early, ra, biotechnology

Rituxan slows joint damage in early RA

Article | 12 January 2009

Print This

US biotechnology firms Genentech and Biogen Idec say that Phase III study data on Rituxan (rituximab) show that it slows ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in